Endocrine Abstracts

see P728....

The serum- and glucocorticoid-regulated kinase 1 (Sgk1) is a direct transcriptional target of glucocorticoids and is post-translationally activated by the insulin/IGF1 pathway. Distinct polymorphisms in the Sgk1 gene are associated with increased body weight and type 2 diabetes. Here we investigate the expression and regulation of Sgk1 in human obesity.In both omental and subcutaneous human adipose tissue, Sgk1 expression is significantly increased in 20...

Serum and glucocorticoid-induced kinase 1 (Sgk1) is an early transcriptional target of glucocorticoids with antiapoptotic effects. Sgk1 becomes active after phosphorylation by growth factors such as insulin and IGF1 through the PI3 kinase/PDK1 pathway. Activated Sgk1 increases the cellular uptake of glucose by increasing the membrane abundance of glucose transporters GLUT1 and GLUT4. Here we present data on the expression and regulation of Sgk1 in adipose tissue using three di...

We present data on open reading frame 62 encoded on human chromosome 6 (C6orf62), a gene whose protein expression and function has not been described to date. The gene product of C6orf62 was designated pituitary associated regulator of hormone secretion (PARS).Initial gene expression screens showed that PARS transcription is differentially regulated in secreting and non-secreting pituitary adenomas, as well as in normal pituitary tissue. Inspired ...

Introduction: Growth differentiation factor 15 (GDF15) has recently been characterized as a cardiovascular risk factor. GDF15 correlates with insulin resistance and obesity in cross-sectional studies and exerts anorexigenic effects in interventional rodent studies. GDF15 has been proposed as a possible therapeutic target in the treatment of obesity, however its meal- and nutrient-dependent regulation in humans has not been investigated previously.Methods...

Glucocorticoid feed-back in pituitary corticotrophs represses POMC transcription and ACTH release. Serum and glucocorticoid-induced kinase 1 (Sgk1) has been identified as an immediate early target of glucocorticoids in many tissues, however its expression and function in corticotrophs are unknown.We show here that Sgk1 is present in the human pituitary gland at both mRNA and protein levels. Double-immunohistochemistry revealed that Sgk1 is expressed in d...

Introduction: In patients with cured Cushing’s syndrome, comorbidities often persist after remission of glucocorticoid excess. Here we investigate long-term comorbidities in patients with Cushing’s syndrome in remission, and their relationship to metabolic and hormonal markers at the initial diagnosis of the disease.Methods/design: We evaluated 118 patients with cured Cushing’s syndrome (55 Cushing’s disease, 55 adrenal Cushing’s...

Introduction: Cushing’s syndrome is associated with significant chronic and acute complications including acute thromboembolic and cardiovascular events. We aimed to study the prevalence and predictors of acute and perioperative complications in patients with active Cushing’s syndrome.Methods: The prevalence, predictors and outcomes of acute, life-threatening and perioperative complications were evaluated in a cohort of patients with active b...

Introduction: Pituitary gigantism is a rare disorder caused by GH-secreting lesions.Aim: We studied gigantism for genetic defects.Methods: We performed genome-wide analyses in 46 patients with gigantism and 248 patients with acromegaly.Results: We detected a novel microduplication at chromosome Xq26.3 in two unrelated kindreds and 13 sporadic cases de novo. All patients had disease onset before five ...